CJC-1295 (no DAC)
Mod GRF 1-29
Sold as 'CJC-1295 without DAC' and more accurately called Mod GRF 1-29, this is a modified 29-amino-acid GHRH fragment altered to resist enzymatic breakdown — and it is not the molecule studied in the published CJC-1295 human trial.
Regulatory status: Not approved by the FDA for any human use and sold only as a research chemical. It is a different molecule from CJC-1295 with DAC, a distinction commercial listings routinely blur.
Default vial
2 mg
Default mix
2 mL
Reported range
100 mcg
Draw (U-100)
10 u
Short-acting GHRH analog, usually dosed AM fasted and pre-bed.
What it is
- A GHRH(1-29) analogue with amino-acid substitutions intended to resist protease degradation, commonly labelled Mod GRF 1-29.
- A GHRH-receptor agonist, the same target class as sermorelin and tesamorelin.
- It lacks the Drug Affinity Complex that gives the DAC version a multi-day half-life, so it is short-acting like native GHRH fragments.
- Typically discussed and sold as a subcutaneous injection product.
How it is described to act
- 1
Presumed to be given subcutaneously, based on how related GHRH(1-29) fragments were dosed in published studies.
- 2
Presumed to distribute like other short GHRH fragments and act at the hypothalamic-pituitary axis.
- 3
Proposed to bind the GHRH receptor on somatotrophs, by analogy with sermorelin's described mechanism.
- 4
Presumed to produce a short GH pulse. No dedicated human GH or IGF-1 outcome trial for this specific molecule was located.
What the research has looked at
What the literature actually contains
- A literature search located no dedicated peer-reviewed human clinical study of Mod GRF 1-29 / 'CJC-1295 without DAC' specifically.
- Everything commonly claimed about it is extrapolated from the related but different sermorelin GHRH(1-29) fragment, or from CJC-1295 with DAC. That is inference, not direct evidence for this compound.
Strength of evidence: Preclinical evidence only
No dedicated human trial for this exact molecule was found. Statements about it in the marketplace are extrapolations from other GHRH peptides.
What is published comes from cell and animal studies. Findings in those models frequently do not carry over to people.
Reported cautions and unknowns
- No compound-specific human safety data were located.
- Injection-site reactions and flushing have been reported for related GHRH-receptor agonists, but that is not direct evidence about this peptide.
- Effects on cortisol, prolactin and IGF-1 specific to this exact peptide are unverified.
References
Handling this vial
- Lyophilized vials are generally stored at 2–8 °C and kept out of light; once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after 28 days.
- Mix by aiming water down the vial wall and rolling gently — do not shake — and never re-freeze a reconstituted vial.
- Pep-Tidy cannot verify what is in your vial. Ask your supplier for a current Certificate of Analysis (HPLC/MS).
CJC-1295 (no DAC) questions people ask
How do you reconstitute CJC-1295 (no DAC)?
A common starting point for a 2 mg vial of CJC-1295 (no DAC) is 2 mL of bacteriostatic water, which gives 1 mg per mL. Aim the water down the inside wall of the vial, let it dissolve on its own, and roll gently instead of shaking. Pep-Tidy's reconstitution calculator will recalculate the numbers for any other vial size or water volume you use.
How many units of CJC-1295 (no DAC) is one dose?
At 1 mg per mL, that works out to about 10 units on a U-100 insulin syringe for a 100 mcg dose. Change the vial size, water volume, or target dose in the calculator and the syringe reading updates with it. This is arithmetic, not a dosing recommendation.
What dosing schedule is reported for CJC-1295 (no DAC)?
Published and community sources describe 100 mcg, subcutaneous, every day, typically run 8 weeks on and 4 weeks off. These figures describe what has been reported, not what anyone should take — talk to a licensed clinician first.
How should CJC-1295 (no DAC) be stored?
Lyophilized CJC-1295 (no DAC) vials are generally kept at 2–8 °C and out of light. Once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after about 28 days. Never re-freeze a reconstituted vial and never shake it.
Read this before you act on anything above
Everything on this page is a summary of what other people have published — it is not medical advice, not a recommendation, and not a dosing instruction. Reported dose ranges describe what appears in the literature or in community protocols, not what anyone should take. Talk to a licensed clinician before using any peptide.